sur The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interest in Avadel Pharmaceuticals plc, as required by the Irish Takeover Panel under Rule 8.3. This disclosure, dated 26 December 2025, reveals that Vanguard holds 5,864,733 US$0.01 ordinary shares, representing a 6.02% stake in the pharmaceutical company.
The filing follows dealings conducted on 24 December 2025, including a purchase of 752 shares at a price of 21.58 USD per share. No derivative or options agreements are reported in this disclosure.
No indemnity, option arrangements, or agreements related to voting rights or future securities transactions were noted. Additionally, Vanguard has not attached any Supplemental Form 8, confirming no further complex financial instruments are involved.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.